Co-Diagnostics (NASDAQ:CODX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Co-Diagnostics (NASDAQ:CODX) to a hold rating in a research report sent to investors on Saturday morning.

A number of other equities analysts have also recently weighed in on the company. Maxim Group upgraded Co-Diagnostics to a “hold” rating in a report on Wednesday, November 26th. HC Wainwright restated a “neutral” rating on shares of Co-Diagnostics in a research note on Monday, November 24th. D. Boral Capital reaffirmed a “buy” rating and set a $90.00 price target on shares of Co-Diagnostics in a report on Tuesday, October 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Co-Diagnostics in a research note on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Co-Diagnostics has a consensus rating of “Hold” and a consensus target price of $55.00.

Co-Diagnostics Stock Up 3.2%

CODX opened at $5.74 on Friday. Co-Diagnostics has a 52-week low of $4.84 and a 52-week high of $46.50. The company has a 50 day moving average of $10.59 and a two-hundred day moving average of $9.89. The company has a market cap of $11.65 million, a P/E ratio of -0.19 and a beta of 1.25.

Co-Diagnostics (NASDAQ:CODX) last issued its earnings results on Thursday, November 13th. The company reported ($4.80) EPS for the quarter, beating analysts’ consensus estimates of ($5.70) by $0.90. Co-Diagnostics had a negative net margin of 6,347.34% and a negative return on equity of 70.26%. The business had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.30 million. Research analysts anticipate that Co-Diagnostics will post -1.22 earnings per share for the current year.

Institutional Trading of Co-Diagnostics

An institutional investor recently raised its position in Co-Diagnostics stock. Virtu Financial LLC lifted its holdings in Co-Diagnostics, Inc. (NASDAQ:CODX) by 393.8% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 126,524 shares of the company’s stock after buying an additional 100,901 shares during the quarter. Virtu Financial LLC owned approximately 0.21% of Co-Diagnostics worth $44,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 14.99% of the company’s stock.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc is a molecular diagnostics company headquartered in Salt Lake City, Utah, known for its proprietary CoPrimer™ technology. Founded in 2016, the company focuses on the design, development and distribution of molecular diagnostic test kits for the detection of infectious diseases, genetic mutations and other health-relevant biomarkers. Its core platform leverages patented cooperative primers, which are engineered to enhance specificity, sensitivity and cost-effectiveness compared to conventional PCR-based assays.

Through its in-house manufacturing and global supply chain partnerships, Co-Diagnostics produces a range of real-time polymerase chain reaction (qPCR) kits, reagents and customized assay development services.